The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: Potential for reversal of cytoprotection by the microenvironment

Blood

Volumn 116, Issue 22, 2010, Pages 4569-4577

  Steele, Andrew J ^a   Prentice, Archibald G ^a   Cwynarski, Kate ^a   Hoffbrand, A Victor ^a   Hart, Stephen M ^a   Lowdell, Mark W ^a   Samuel, Edward R ^a   Wickremasinghe, R Gitendra ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYTOCHROME C; FLUDARABINE; INTERLEUKIN 4; JANUS KINASE 3 INHIBITOR; LIPOCORTIN 5; NUTLIN 3; PF 956980; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL XL; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN MCL 1; PROTEIN P53; STAT6 PROTEIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CELL PROTECTION; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME METABOLISM; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; LYMPHOCYTE CULTURE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; T LYMPHOCYTE; UPREGULATION;

EID: 78649457614     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-245811     Document Type: Article

References (48)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
2. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment. Blood. 2009;114(16):3367-3375.
3. Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107(9):3584-3592.
4. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F. How I treat refractory CLL. Blood. 2006;107(4):1276-1283.
5. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood. 2008;112(9):3827-3834.
6. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing "high risk" subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007;21(9):1885-1891.
7. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665-674.
8. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701-738.
9. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro.Br J Haematol. 1993;85(3):439-445.
10. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-β. Blood. 1997;89(3):941-947.
11. Zheng Z, Venkatapathy S, Rao G, Harrington CA. Expression profiling of B-cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion, and increased intracellular protein transport and processing of leukemic cells. Leukemia. 2002;16(12):2429-2437.
12. + T-cell subset in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;104(3):589-599.
13. Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia. 2008;22(5):1084-1087.
14. Kay NE, Han L, Bone N, Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol. 2001;112(3):760-767.
15. Rossmann ED, Lewin N, Jeddi-Tehrani M, Osterborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol. 2002;68(5):299-306.
16. Walker KF, Lappin DF, Takahashi K, Hope J, Macdonald DG, Kinane DF. Cytokine expression in periapical granulation tissue as assessed by immunohistochemistry. Eur J Oral Sci. 2000;108(3):195-201.
17. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441-4450.
18. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.Br J Haematol. 1996;92(1):97-103.
19. Burger JA, Kipps TJ. CXCR4: a key receptor in the cross-talk between tumor cells and their microenvironment. Blood. 2006;107(5):1761-1767.
20. Vila-Coro AJ, Rodríguez-Frade JM, Martín De Ana A, Moreno-Ortíz MC, Martínez AC, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999;13(13):1699-1710.
21. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells, but not normal B cells, are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91(7):2387-2396.
22. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008;111(4):2155-2157.
23. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
24. Jones DT, Ganeshaguru K, Virchis AE, et al. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood. 2001;98(9):2800-2807.
25. Vianello F, Villanova F, Tisato V, et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 2010;95(7):1081-1089.
26. Jones DT, Addison E, North JM, et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augments the cells' sensitivity to cytotoxic drugs. Blood. 2004;103(5):1855-1861.
27. Galluzzi L, Aaronson SA, Abrams J, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009;16(8):1093-1107.
28. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia. 2007;21(8):1773-1782.
29. Steele AJ, Prentice AG, Hoffbrand AV, et al. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood. 2009;114(6):1217-1225.
30. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008;415(3):333-344.
31. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848.
32. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;(8)2:594-604.
33. Chipuk JE, Green DR. Cytoplasmic p53: bax and forward. Cell Cycle. 2004;3(4):429-431.
34. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205-219.
35. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747-758.
36. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 1991;5(2):171-177.
37. Briscoe J, Guschin D, Rogers NC, et al. JAKs, STATs, and signal transduction in response to the interferons and other cytokines. Philos Trans R Soc Lond B. 1996;351(1336):167-171.
38. Jones DT, Ganeshaguru K, Anderson RJ, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. Blood. 2003;101(8):3174-3180.
39. Barragán M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C beta. J Leuk Biol. 2006;80(21):1473-14799.
40. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19(21):2474-2488.
41. Buettner R, Mora LB, Jove R. Activated STAT signalling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8(4):945-954.
42. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT)1 and STAT3 constitutively phosphorylated on tyrosine residues. J Clin Invest. 1997;100(12):3140-3148.
43. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112(1):188-195.
44. Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Yoshikai Y. Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-XL expression. J Biol Chem. 2001;276(28):26107-26113.
45. Ritz O, Guiter C, Dorsch K, et al. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia. 2008;22(11):2106-2108.
46. Pepper C, Lin TT, Pratt G, Hewamana S, et al. Mcl-1 expression has in vitro and in vivo signifi- cance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112(9):3807-3817.
47. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105(12):4820-4827.
48. Ghoreschi K, Laurence A, O'Shea JJ. Selective and therapeutic inhibition of kinases: to be or not to be. Nat Immunol. 2009;10(1):356-360.